IPO Synopsis
| Nephrocare Health Services Ltd |
|---|
| Registered Office: 5th Flr D Block iLabs Centre,Plot 18 Software Units Sy.#.64,Hyderabad-500081, Telangana |
| Tel. No: +91 40 4240 8039 |
| Fax No: NA |
| Email: cs@nephroplus.com |
| Website: www.nephroplus.com |
| Initial public offering of 18,943,020 equity shares of face value of Rs.2/- each ("equity shares") of Nephrocare Health Services Limited ("the company" or the "company" or the "issuer") for cash at a price of Rs.460/- per equity share face value of Rs.2/- (including a securities premium of Rs.458/- per equity share) ("offer price") aggregating to Rs.871.05 crores ("offer") comprising a fresh issue of 7,690,162 equity shares of face value of Rs.2/- each aggregating to Rs.353.41 crores ("fresh issue") and an offer for sale of 11,253,102 equity shares of face value of Rs.2/- each ("offered shares") aggregating to Rs.517.64 crores , comprising an offer for sale of 1,521,728 equity shares of face value of Rs.2/- each aggregating to Rs.70.00 crores by Investcorp Private Equity Fund II and 1,604,907 equity shares of face value of Rs.2/- each aggregating to Rs.73.83 crores by Healthcare Parent Limited and 147,765 equity shares of face value of Rs.2/- each aggregating to Rs.6.80 crores by Investcorp Growth Opportunity Fund and 2,888,911 equity shares of face value of Rs.2/- each aggregating to Rs.132.89 crores by Edoras Investment Holdings Pte. Ltd. ("promoter selling shareholders") and 121,985 equity shares of face value of Rs.2/- each aggregating to Rs.5.61 crores by Investcorp India Private Equity Opportunity Limited and 3,089,663 equity shares of face value of Rs.2/- each aggregating to Rs.142.12 crores by International Finance Coproration and 1,433,468 equity shares of face value of Rs.2/- each aggregating to Rs.65.94 crores by 360 One Special Opportunities Fund - Series 9 and 444,675 equity shares of face value of Rs.2/- each aggregating to Rs.20.46 crores by 360 One Special Opportunities Fund - Series 10 ("other selling shareholders" and together with the promoter selling shareholders, the "selling shareholders" and such offer for sale by the selling shareholders, the "offer for sale"). The offer constituted 18.88% of the post-offer paid-up equity share capital of the company. |
| Issue | Money Payable On | ||
|---|---|---|---|
| Opens On | Closes On | Application | |
| 10-Dec-2025 | 12-Dec-2025 | ₹460.00 - 0.00 | |
| Minimum Application for shares in Nos : 32.0 | Further Multiples of :32.0 |
|---|
| (₹ Cr) | Lead Managers to the Issue | |
|---|---|---|
| Project Cost | 325.15 | Ambit Private Limited |
| Project Financed through Current Offer | 871.05 | ICICI Securities Limited |
| Post Issue Equity Share Capital | 20.07 | IIFL Capital Services Limited |
| Issue Price | 460.00 | Nomura Financial Advisory & Securities (I) Pvt Ltd |
| Projects |
|---|
| Capital expenditure by our Company for opening new dialysis clinics in India |
| Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by our Company |
| General corporate purposes |
| Promoted By |
|---|
| Vikram Vuppala |
| Bessemer Venture Partners Trus |
| Edoras Investment Holdings Pte |
| Listing At |
|---|
| BSE |
| NSE |
| Registrar To The Issue |
|---|
